Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.47
(-2.97%)
USD 1.47
(-2.97%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -36.8 Million USD | 15.45% |
| 2022 | -43.02 Million USD | -75.93% |
| 2021 | -24.45 Million USD | -209.05% |
| 2020 | -7.91 Million USD | 75.06% |
| 2019 | -31.73 Million USD | -17.68% |
| 2018 | -26.96 Million USD | -33.47% |
| 2017 | -20.2 Million USD | 33.04% |
| 2016 | -30.17 Million USD | -206.27% |
| 2015 | -9.85 Million USD | 8.42% |
| 2014 | -10.75 Million USD | -12.19% |
| 2013 | -9.58 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -20.46 Million USD | 36.77% |
| 2024 Q1 | -32.36 Million USD | 11.03% |
| 2023 Q2 | -28.78 Million USD | 31.7% |
| 2023 Q1 | -42.14 Million USD | 2.03% |
| 2023 FY | -36.37 Million USD | 15.45% |
| 2023 Q4 | -36.37 Million USD | 1.4% |
| 2023 Q3 | -36.89 Million USD | -28.16% |
| 2022 Q2 | -65.7 Million USD | -95.48% |
| 2022 Q1 | -33.61 Million USD | -37.44% |
| 2022 Q3 | -59.27 Million USD | 9.79% |
| 2022 FY | -43.02 Million USD | -75.93% |
| 2022 Q4 | -43.02 Million USD | 27.41% |
| 2021 FY | -24.45 Million USD | -209.05% |
| 2021 Q2 | -99.51 Million USD | -368.94% |
| 2021 Q1 | -21.22 Million USD | -149.18% |
| 2021 Q4 | -24.45 Million USD | 51.62% |
| 2021 Q3 | -50.55 Million USD | 49.2% |
| 2020 Q2 | -18.76 Million USD | 53.12% |
| 2020 FY | -7.91 Million USD | 75.06% |
| 2020 Q4 | -8.51 Million USD | 14.65% |
| 2020 Q3 | -9.97 Million USD | 46.82% |
| 2020 Q1 | -40.01 Million USD | -30.69% |
| 2019 Q4 | -30.61 Million USD | -889.73% |
| 2019 Q3 | 3.87 Million USD | 19.77% |
| 2019 Q2 | 3.23 Million USD | 387.22% |
| 2019 Q1 | -1.12 Million USD | 95.84% |
| 2019 FY | -31.73 Million USD | -17.68% |
| 2018 Q4 | -27.1 Million USD | -1.94% |
| 2018 FY | -26.96 Million USD | -33.47% |
| 2018 Q1 | -54.88 Million USD | -171.66% |
| 2018 Q2 | -46.03 Million USD | 16.12% |
| 2018 Q3 | -26.59 Million USD | 42.24% |
| 2017 Q2 | -32.7 Million USD | -38.14% |
| 2017 FY | -20.2 Million USD | 33.04% |
| 2017 Q4 | -20.2 Million USD | 66.36% |
| 2017 Q1 | -23.67 Million USD | 21.52% |
| 2017 Q3 | -60.05 Million USD | -83.61% |
| 2016 FY | -30.17 Million USD | -206.27% |
| 2016 Q4 | -30.17 Million USD | -69.54% |
| 2016 Q3 | -17.79 Million USD | 44.06% |
| 2016 Q2 | -31.81 Million USD | -142.29% |
| 2016 Q1 | -13.13 Million USD | -33.3% |
| 2015 Q2 | -9.85 Million USD | -161.08% |
| 2015 Q3 | -25.41 Million USD | -157.98% |
| 2015 Q4 | -9.85 Million USD | 61.25% |
| 2015 FY | -9.85 Million USD | 8.42% |
| 2015 Q1 | 16.12 Million USD | 249.95% |
| 2014 Q4 | -10.75 Million USD | 0.0% |
| 2014 FY | -10.75 Million USD | -12.19% |
| 2014 Q1 | 13.32 Million USD | 0.0% |
| 2013 FY | -9.58 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 64.251% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -17.897% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 118.582% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 215.427% |
| bluebird bio, Inc. | 108.57 Million USD | 133.899% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -308.208% |
| Imunon, Inc. | -4.69 Million USD | -683.185% |
| Editas Medicine, Inc. | -87.11 Million USD | 57.753% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.286% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 101.754% |
| Myriad Genetics, Inc. | 88.1 Million USD | 141.775% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 120.758% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -9.774% |
| Verastem, Inc. | -37.27 Million USD | 1.272% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.447% |
| Waters Corporation | 1.96 Billion USD | 101.877% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.137% |
| Biogen Inc. | 6.28 Billion USD | 100.585% |
| Nektar Therapeutics | 210.24 Million USD | 117.506% |
| Perrigo Company plc | 3.32 Billion USD | 101.108% |
| Dynavax Technologies Corporation | 106.63 Million USD | 134.514% |
| Illumina, Inc. | 1.21 Billion USD | 103.032% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 628.18% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 67.684% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 125.369% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 612.091% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 109.717% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -418.366% |
| Evolus, Inc. | 63.7 Million USD | 157.77% |
| Adicet Bio, Inc. | -142 Million USD | 74.083% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -35.808% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 108.024% |
| FibroGen, Inc. | 56.76 Million USD | 164.833% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 103.214% |
| OPKO Health, Inc. | 230.68 Million USD | 115.954% |
| Homology Medicines, Inc. | 18.43 Million USD | 299.62% |
| Geron Corporation | 14.76 Million USD | 349.333% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 102.322% |
| Exelixis, Inc. | -73.05 Million USD | 49.618% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 32.166% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 75.63% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 66.963% |
| Zoetis Inc. | 4.76 Billion USD | 100.773% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 81.582% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -265.445% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.615% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -152.567% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 103.491% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.801% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 72.818% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.665% |
| Blueprint Medicines Corporation | 702.83 Million USD | 105.236% |
| Insmed Incorporated | 721.62 Million USD | 105.1% |
| TG Therapeutics, Inc. | 17.86 Million USD | 306.046% |
| Incyte Corporation | -3.17 Billion USD | 98.841% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 104.806% |